Stockscreener 앱 받기
0.00
100.00%
-0.30
전일 마감가:
$0.30
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$1.13M
수익:
$132.70K
순이익/손실:
$-25.04M
주가수익비율:
0.00
EPS:
-413.2312
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$3.49
Altamira Therapeutics Ltd Stock (CYTO) Company Profile
CYTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTO
Altamira Therapeutics Ltd
|
0.00 | 1.13M | 132.70K | -25.04M | 0 | -413.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.76 | 121.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.66 | 74.96B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
640.14 | 38.90B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.51 | 32.43B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.58 | 28.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altamira Therapeutics Ltd 주식(CYTO)의 최신 뉴스
In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability - ACCESS Newswire
Auris Medical and King's College London Extend Tinnitus Collaboration -February 22, 2017 at 08:02 am EST - Marketscreener.com
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 - ACCESS Newswire
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries - ACCESS Newswire
Altamira Therapeutics Ltd. Announces Collaboration on Radiopharmaceutical Targeting Strategies - Marketscreener.com
Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies - GlobeNewswire
Altamira Therapeutics achieves nanoparticle-based delivery of circular mRNA - BioWorld Online
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA - The Manila Times
Altamira Therapeutics Ltd. Announces Successful Nanoparticle-Based Delivery of Circular RNA - Marketscreener.com
Nasdaq de-lists Altamira shares - Royal Gazette
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Marketscreener.com
Altamira Therapeutics Moves to OTCQB After Nasdaq Delisting Over Minimum Bid Requirements - StockTitan
Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 1.3% – Here’s What Happened - Defense World
Loud and clear: Sound Pharma has phase III success in Meniere’s - BioWorld Online
CYTO stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com South Africa
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne
Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India
Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times
Altamira Therapeutics Faces Nasdaq Delisting - TipRanks
Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa
CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa
Altamira Medica obtains extended ISO 13485 certification - Investing.com
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan
Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia
Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey
Altamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ... By GuruFocus - Investing.com Canada
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics - Digital More
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics announces $4 million public offering - Investing.com India
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio - GlobeNewswire
Altamira Therapeutics Ltd (CYTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
3.04%
자본화:
|
볼륨(24시간):